1. Background {#s0005}
=============

Following the results in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) [@b0005], sacubitril/valsartan was endorsed by the latest (2016) recommendations from the European Society of Cardiology (ESC) for the management of chronic heart failure (CHF) patients [@b0010]. Data from real life studies seem to confirm excellent results of randomized studies [@b0015], [@b0020].

Observational studies have also demonstrated that treatment with sacubitril/valsartan may improve left ventricular systolic and diastolic function [@b0025] in subjects with reduced left ventricular ejection fraction (LVEF), reverse remodeling [@b0030], NYHA functional class [@b0035]. Sacubitril/valsartan also reduced costs of hospitalization in real world registries [@b0040].

Subjects with HF and reduced EF (HFrEF), however, are also characterized by an impaired right ventricular (RV) function. The compresence of RV dysfunction indicates HF progression and may carry an additional worse prognostic value, while RV recovery is associated with an improved outcome [@b0045].

On the base of such evidence, we sought to evaluate whether treatment with sacubitril/valsartan may also improve RV function in subjects with HFrEF in an observational study.

2. Methods {#s0010}
==========

Sixty consecutive patients with HFrEF in NYHA functional class II-III, enrolled in the Daunia Heart Failure Registry as reported elsewhere [@b0050], [@b0055], [@b0060], were followed up between September 2016 and January 2019. Enrollment criteria included LVEF ≤ 35%, systolic blood pressure ≥ 100 mmHg, eGFR ≥ 30 mL/min/1.73 m^2^, potassium levels ≤ 5.4 mmol/l. All patients were treated with stable ACE-inhibitor or angiotensin receptor antagonist doses for at least 6 months and started treatment with sacubitril/valsartan therapy as recommended by the 2016 ESC guidelines on HF diagnosis and treatment ^2^. Medical history, heart rate, systolic blood pressure, Body Mass Index, NYHA functional class, and medications were recorded and monitored. All patients underwent blood analysis, ECG and conventional and TDI echocardiography in an ambulatory setting under resting conditions at the beginning and after 12 months of therapy with sacubitril/valsartan.

2.1. Echocardiography {#s0015}
---------------------

Conventional echocardiography was used to assess LV dimensions and LVEF, peak velocities of *trans*-mitral early (E) and late diastolic (A) LV filling, the ratio of *trans*-mitral early to late (E/A ratio) LV filling velocity. LV dimensions and LVEF were calculated as recommendations in the joint ASE/ESC guidelines. LVEF was calculated according to the Simpson's rule.

The TAPSE (tricuspid annular plane systolic excursion) was measured using apical views adjusted to optimize RV structures and to achieve proper orientation for M−mode measures.

Pulsed Doppler mitral inflow velocities were obtained by placing a 1--2 mm sample volume between the tips of the mitral leaflets in the apical four-chamber view. The Doppler beam was aligned parallel to the direction of flow. TDI measurements recorded at the septal mitral annulus in apical four-chamber view included early (E') diastolic velocities. The *trans*-mitral to mitral annular early diastolic velocity ratio (E/E\') was also calculated.

The peak tricuspid regurgitation velocity was assessed by placing the continuous Doppler through the tricuspid valve and the degree of tricuspid regurgitation was evaluated by the color mode.

Pulmonary artery systolic pressures (PAsP) were estimated using the approach of calculating the systolic pressure gradient between right ventricle and right atrium by the maximum velocity of the tricuspid regurgitant jet using the modified Bernoulli equation and then adding to this value the estimated right atrial pressures based on both the size of the inferior vena cava and the change in caliber of this vessel with respiration, according to international recommendations.

Transthoracic echocardiography was performed using an EPIQ 7C ultrasound system with X5-1 matrix array transducer (Philips Healthcare). All echocardiographic studies were performed and interpreted by experienced physicians. They were blinded of the clinical data.

2.2. Statistical analysis {#s0020}
-------------------------

Continuous variables were expressed as mean ± standard deviation and compared with Student\'s *t*-test, categorical variables as percentages and compared with χ^2^ test. Mean values were compared with Student\'s *t*-test for variables with a normal distribution or with the Mann--Whitney non-parametric *U* test for variables with a non-normal distribution. Linear correlations were determined by measuring the Pearson's correlation coefficient. Multivariable regression analysis was used to assess possible bias of confounders. A p \< 0.05 was considered as statistically significant.

3. Results {#s0025}
==========

Mean age was 66 ± 9 years, LVEF 34 ± 9%, male patients were 88%, NYHA class III represented 29%, hypertension was present in 57%, ischemic heart disease in 43%, diabetes in 31%, COPD in 31%, 50% had an ICD/CRT-D implanted. All patients were treated with beta-blockers, 29% with ivabradine, 57% with mineral-corticoid receptor inhibitors. Population characteristics are given in [Table 1](#t0005){ref-type="table"}.Table 1Population's characteristics.Mean ± SE(%)Age (years)66 ± 9Male (%)88%Heart rate (bpm)70 ± 14Systolic blood pressure (mmHg)123 ± 20Ischemic etiology (%)43%Hypertension (%)57%COPD (%)31%Diabetes (%.)31%ICD/CRT-D (%)50%LVEF (%)34 ± 9LVESV120 ± 56LVEDV176 ± 70E/E' ratio15.5 ± 5.7PAsP34 ± 12TAPSE16.5 ± 4.05Creatinine (mg/dl)1.16 ± 4.04ACE inhibitor (%)68%ARB (%)32%Furosemide (%)85%MRA (%)57%Betablocker (%)96%Ivabradine (%.)29%Digoxin (%)13%[^1]

At 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (34.0 ± 9.2 vs 39.5 ± 9.8%, p \< 0.05), LV end-systolic volume (121.6 ± 55.9 vs 108.2 ± 55.2 mL, p \< 0.01), left atrium area (24.9 ± 6.9 vs 23.4 ± 6.3 cm^2^, p \< 0.05) **(**[Table 2](#t0010){ref-type="table"}**)**.Table 2Differences between baseline and follow-up parameters.VariablesBaseline valuesFollow-up valuesP-levelNYHA F. C.2.3 ± 0.52.3 ± 0.5n.s.Tricuspid regurgitation1.0 ± 0.551.0 ± 0.52n.s.sPAP34.7 ± 12.531.0 ± 12.8\<0.05TAPSE16.5 ± 4.017.8 ± 3.9\<0.001Systolic Blood Pressure123.3 ± 19.8115.8 ± 23.8\<0.01HR70.3 ± 14.467.0 ± 9.7\<0.05LVEF34.0 ± 9.239.5 ± 9.8\<0.001LVEDV177.3 ± 71.1174.4 ± 70.1n.s.LVESV121.6 ± 55.9108.6 ± 55.2\<0.01E/E' ratio15.7 ± 5.615.1 ± 6.2n.s.Left atrium area24.9 ± 6.923.4 ± 6.3\<0.05NT-pro-BNP3049.1 ± 5775.12305.2 ± 6768.4n.s.[^2][^3]

RV echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 ± 12.8 vs 34.7 ± 12.5 mmHg, p \< 0.05), TAPSE (17.8 ± 3.9 vs 16.5 ± 4.0 mm, p \< 0.001) ([Fig. 1](#f0005){ref-type="fig"}); mean PAsP reduction was 3.7 ± 11.4 mmHg (-6.3 ± 37.7%), mean TAPSE increase 1.3 ± 2.5 mm (+9.5 ± 15.7%).Fig. 1Systolic pulmonary arterial pression (p \< 0.05) and TAPSE (p \< 0.001) improvement after 12-month therapy with sacubitril/valsartan.

Indexed (%) improvement in PAsP (r 0.33, p \< 0.01) and TAPSE (r −0.42, p \< 0.01) values were proportional to baseline levels ([Fig. 2](#f0010){ref-type="fig"}). Improvement in PAsP and TAPSE were independent of LV improvements except for PAsP and end-systolic volumes (r 0.44, p \< 0.01).Fig. 2Linear correlation between baseline sPAP (r 0.33, p \< 0.01) and TAPSE (r −0.42, p \< 0.01) levels and indexed (%) changes after 12-month therapy with sacubitril/valsartan.

At multivariable analysis improvement in RV function was independent from age, gender, LV end-systolic and LVEF improvement after sacubitril/valsartan therapy (p \< 0.05) ([Table 3](#t0015){ref-type="table"}); PAsP changes were proportional to LV end-systolic changes even at multivariable analysis (p \< 0.01).Table 3Multivariable regression analysis.b\*Std.Err.bStd.Err.p-valueTAPSEage−0.11970.1590−0.00200.00270.4565male−0.18790.1518−0.09090.07340.2240variation in end-systolic volume0.30640.18620.18520.11260.1089variation in LVEF0.19730.16550.11640.09760.2412variation in PAsP−0.26930.1675−0.11240.06990.1170baseline TAPSE−0.32800.1556−0.01270.00600.0423PAsPage−0.16850.1288−0.00670.00510.1975male−0.05750.1270−0.06660.14710.6531variation in end-systolic volume0.48690.13930.70530.20170.0011variation in LVEF0.16680.14060.23590.19880.2417Baseline PAsP0.26300.12690.00810.00390.0441[^4]

4. Discussion {#s0030}
=============

To the best of our knowledge, this is the first study showing an improved RV function after therapy with sacubitril/valsartan in a real world registry. Improvements in RV function were proportional to baseline dysfunction and not entirely related to improvement in LV function.

In CHF, development of RV dilation and failure are signs of HF progression carrying an increased risk of cardiac death, irrespective of degree of LV dysfunction [@b0065], [@b0070], [@b0075], [@b0080], [@b0085], [@b0090]. A reduced TAPSE is associated with a higher risk of death or hospitalization during follow-up ^13\ 17^ [@b0095]. This parameter has been shown to be an important prognostic marker in patients with HF secondary to ischaemic or non-ischemic dilated cardiomyopathy, either when assessed alone ^13\ 19^ [@b0100] or in combination with PAsP [@b0105]. The prognostic role of TAPSE was significantly maintained in multivariable models [@b0110], [@b0115].

In our study we found a positive effect of sacubitril/valsartan therapy on these RV parameters (TAPSE and PAsP) in HFrEF outpatients, in a real-world scenario of patients with CHF. Our findings are in line with previous animal model studies showing that Sacubitril/Valsartan was associated with statistically significant improvement in LVEF [@b0120]. In other animal experimental models, sacubitril/valsartan resulted in superior cardiovascular benefits, as evidenced by sustained improvements in LVEF and end‐diastolic pressure [@b0125]. Ex vivo vascular function, as measured by aortic vasorelaxation responses to acetylcholine and sodium nitroprusside, was significantly improved by valsartan and sacubitril/valsartan, with more sustained improvements achieved by sacubitril/valsartan.

A lack of neprilysin or its reduced expression in hypoxia experimental models led to exacerbation of pulmonary arterial remodelling or pulmonary hypertenion (PH) [@b0130] and to a platelet-derived growth factor levels increase in pulmonary artery smooth muscle cells [@b0135]. The increased platelet-derived growth factor levels result in the proliferation and migration of pulmonary artery smooth muscle cells and endothelial-to-mesenchymal transition [@b0140].

In preclinical studies on rats with PH, sacubitril/valsartan reduced RV systolic pressure, RV hypertrophy, and dilatation [@b0145]; these effects may be secondary to pulmonary vascular changes, including reduced pulmonary vascular remodeling, as demonstrated by reduction of pulmonary vascular wall thickness in rats with PH in treatment with sacubitril/valsartan [@b0150].

PH due to left heart disease (PH-LHD) frequently complicates HFrEF; sacubitril/valsartan increases levels of natriuretic peptides. The resulting action on natriuresis, diuresis and vasodilation may play an important role in the reduction of pulmonary pressures and so the sacubitril/valsartan may affect RV function.

In our study, patients with lower TAPSE or high PASP showed more benefit with therapy than others maybe because, in such patients, higher levels of neprilysin could be hypothesized alongside with a more relevant effect on pulmonary vascular remodelling.

A *meta*-analysis of over 69,000 patients by Kramer et al. demonstrated that improvement in LVEF and LV remodeling parameters was associated with lower rates of mortality among patients with HFrEF [@b0155]. Also RV recovery was associated with improved survival in HF patients [@b0045].

How to impact RV impaired function remains, however, an unresolved issue. There are inconsistent data on RV positive remodeling after standard therapy for HFrEF. In a small cohort of patients with HF and RV dysfunction, carvedilol administration was safe and it was associated with positive RV remodelling as well as improved exercise duration [@b0160].

In a multicenter, randomized, double-blind, placebo-controlled, crossover clinical trial in patients with systemic RV dysfunction, losartan did not improve exercise capacity or reduce NT-proBNP levels [@b0165]. The majority of the studies, however, was held in congenital heart disease treated with heart surgery [@b0170].

Also matter of debate is whether the improvement in RV function is mediated by improvement in LV function or not.

Our data are the first showing an improved RV function with a new class of drugs, sacubitril/valsartan. However, these results require confirmation in larger cohorts with longer follow-up periods.

5. Conclusions {#s0035}
==============

In a real world scenario, sacubitril/valsartan was associated with an improved RV function.

6. Limitations {#s0040}
==============

Main limitations of the study are represented by the small number of patients enrolled and the observational nature of the study; these preliminary results need to be confirmed in a properly powered multicentric study and randomized trials.
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[^1]: Legend: COPD: Chronic Obstructive Pulmonary Disease; ICD/CRT-D: Implantable Cardioverter-Defibrillator/Cardiac Resynchronization Therapy-Defibrillator; LVEF: Left Ventricular Ejection Fraction; LVEDV: Left Ventricle End-Diastolic Volume; LVESV: Left Ventricular End-Systolic Volume; E/E' ratio: *trans*-mitral to mitral annular early diastolic velocity ratio; PAsP: Pulmonary Artery systolic Pressure; TAPSE: Tricuspid Annular Plane Systolic Excursion; ACE: Angiotensin Converting Enzyme; ARB: Angiotensin II Receptor Blocker; MRA: Mineralocorticoid Receptor Antagonist.

[^2]: Legend: NYHA F.C.: New York Heart Association Functional Class; PAsP: Pulmonary Artery systolic Pressure; TAPSE: Tricuspid Annular Plane Systolic Excursion; HR: Heart Rate; LVEF: Left Ventricular Ejection Fraction; LVEDV: Left Ventricle End-Diastolic Volume; LVESV: Left Ventricular End-Systolic Volume; E/E' ratio: *trans*-mitral to mitral annular early diastolic velocity ratio; NT-pro-BNP: N-terminal fragment of pro-BNP; BNP: B-type natriuretic peptide.

[^3]: Tricuspid regurgitation is expressed in a semi-quantitative scale from 0 to 3.

[^4]: Legend. TAPSE: Tricuspid Annular Plane Systolic Excursion; LVEF: left ventricular ejection fraction; PAsP: pulmonary arterial systolic pressure.
